Navigation Links
Blood Cancer Drug Shows Promise Against Lupus
Date:6/8/2008

Experiments with mice found Velcade reduced dangerous autoantibodies

SUNDAY, June 8 (HealthDay News) -- A drug used to treat multiple myeloma, a cancer of the white blood cells, may also be a treatment for the chronic autoimmune disease lupus, German researchers report.

The drug, Velcade (bortezomib), which is a proteasome inhibitor, worked against the disease and prolonged survival in mice with lupus. The finding could one day offer treatment options for other antibody-associated diseases, too, the researchers said.

"Autoantibody-mediated diseases such as autoimmune hemolytic anemia, immune thrombocytopenia, myasthenia gravis and systemic lupus erythematosus are often difficult to treat," said lead researcher Dr. Reinhard Voll, of the University of Erlangen-Nuremberg.

A big problem is that plasma cells, which are the predominant producers of the disease-causing autoantibodies, can't be efficiently attacked with current treatments, Voll said.

Lupus is a so-called autoimmune disease in which the immune system attacks healthy cells and tissues by mistake, leading to damage to joints, skin, blood vessels and organs. There are many kinds of lupus, with the most common type being systemic lupus erythematosus, which affects many parts of the body. There's no one test to diagnose lupus, and it may take months or years to make the diagnosis. There's also no cure, but medicines and lifestyle changes can help control the disease, according to the U.S. National Institutes of Health

For the new study, Voll's team found that bortezomib efficiently eliminated the plasma cells in the mice, leading to a drastic decrease in autoantibodies and prolonged survival. And, the drug had no effect on other cells, he said.

"Proteasome inhibitors may be beneficial in refractory human diseases caused predominantly by autoantibodies," Voll said. "Proteasome inhibitors can selectively deplete plasma cells, which are resistant to current treatments."

Outside experts were divided on the findings, published in the June 8 online edition of Nature Medicine.

"This is a very exciting study that explores a novel mechanism for treating lupus erythematosus," said Dr. Jennifer Grossman, an assistant professor of medicine at the University of California, Los Angeles.

"The fact that antibodies almost completely disappeared is encouraging. I look forward to hearing more about this treatment in the future," she said.

But, another expert expressed concern that the treatment could adversely affect other cells in the human body.

"I think they're onto something important, it looks as if it has a remarkable therapeutic effect," said Dr. Noel Rose, director of the Autoimmune Disease Research Center at Johns Hopkins University. "The downside is that this is a proteasome inhibitor, and there is no reason to think that it would be specific for plasma cells. It does affect other rapidly proliferating cells."

Rose noted that many drugs may appear safe during an initial trial. "I'm still really suspicious that if this is used clinically, there are going to be side effects like effects on intestinal or other rapidly dividing cells," he said. "The question is, are the side effects going to be severe enough to prevent the use of this drug?"

More information

To learn more about lupus, the U.S. National Library of Medicine.



SOURCES: Reinhard Voll, M.D., University of Erlangen-Nuremberg, Erlangen, Germany; Jennifer Grossman, M.D., assistant professor of medicine, University of California, Los Angeles; Noel Rose, M.D., director, Autoimmune Disease Research Center, Johns Hopkins University, Baltimore; June 8, 2008, Nature Medicine, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Having heart surgery? Watch your blood sugar, especially if youre overweight or older
2. Scientists ID Gene Regulating Blood Glucose Levels
3. Studies Differ on Benefits of Aggressive Blood Sugar Control
4. MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
5. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
6. New Yorks Catholic Archdiocese Hosting June 2 Blood Drive
7. Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese
8. Special supplement on self-monitoring of blood glucose in diabetes technology & therapeutics
9. Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics
10. No association found between vitamin D concentration in blood and risk of prostate cancer
11. International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the ... kicking trainers to St. Jude Children’s Research Hospital to benefit families dealing with ... band designed to teach children how to kick a soccer ball correctly. The ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provider serving families of Camas and Vancouver, WA, has announced the latest ... the National Breast Cancer Foundation and their Mammography Program, which provides free ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, Inc., one ... of the innovative newly improved Iso-Hip Wrap. The newly designed hip wrap ... enhances comfort and enables the patient to enjoy the benefits of cold therapy ...
(Date:5/4/2016)... , ... May 04, 2016 , ... A new collaboration ... world. The Duke Clinical Research Institute (DCRI) and analytics leader SAS will provide researchers ... data collected by the Duke University Health System. , The DCRI and SAS ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
Breaking Medicine Technology: